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angiogenesisKaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), an AIDS-
related endothelial cell malignancy that is the most common cancer in central and southern Africa. The KSHV
viral G protein-coupled receptor (vGPCR) is a viral oncogene that conveys a survival advantage to
endothelial cells and causes KS-like tumors in mouse models. In this study we investigate the role of Shp2, a
protein tyrosine phosphatase in vGPCR signaling. Shp2 is vital to many cytokine-induced signaling pathways
and is dysregulated in various infections and malignancies. It has also recently been implicated in
angiogenesis. We ﬁnd that vGPCR activity results in phosphorylation of regulatory tyrosines in Shp2 and that
in turn, Shp2 is required for vGPCR-mediated activation of MEK, NFκB, and AP-1. Furthermore, both genetic
and chemical inhibition of Shp2 abrogate vGPCR-induced enhancement of endothelial cell migration. This
establishes Shp2 as an important point of convergence of KSHV vGPCR signaling and a potential molecular
target in the design of an anti-KSHV therapeutic regimen.
© 2009 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma (KS) is a highly angiogenic endothelial cell tumor
that is among the most common AIDS-related malignancies world-
wide. The burden of disease varies geographically but is particularly
striking in central and southern Africa. The etiologic agent, Kaposi's
sarcoma-associated herpesvirus (KSHV), was discovered in 1994 and
is required for all epidemiologic types of KS (Chang et al., 1994;Whitby
et al., 1995). In addition to endothelial cells, KSHV can also be found in
lymphnodes, peripheral blood B cells, and is a driving force in all forms
of primary effusion lymphoma (PEL), a neoplasm that accounts for 3-
5% of AIDS-related non-Hodgkins lymphomas (Cesarman et al., 1995;
Moore et al., 1996; Nador et al., 1996; Said et al., 1996). As with other
human herpesviruses, not all KSHV infected individuals display
pathologic sequelae. It is clear that HIV infection or other non-HIV
immunomodulatory co-factors must be present. It has been hypoth-
esized that at least in its early stages, KS is a cytokine driven process
(Della Bella et al., 2008; Monini et al., 1999). How the cytokine milieu
in the tumor microenvironment is established and maintained and
how it in turn supports viral propagation and tumor progression is still
being deﬁned. Lesions are a complex mix of proliferating KS “spindle”, The University of Minnesota,
5, USA. Fax: +1 612 626 9924.
ll rights reserved.cells, inﬂammatory cells and aberrant angiogenesis. There are many
viral proteins that affect these processes either directly or via paracrine
mechanisms.
The KSHV-encoded chemokine receptor, vGPCR, has the potential
to play roles in angiogenesis, cell cycle regulation, and possibly the
viral life cycle (Bais et al., 1998; Cannon, Cesarman, and Boshoff, 2006).
KSHV vGPCR is a constitutively active homologue of the human IL-
8 receptor CXCR2 presumably pirated from the host genome at some
point during co-evolution with subsequent acquisition of activating
mutations (Arvanitakis et al., 1997; Cesarman et al., 1996; Guo et al.,
1997). Unlike its mammalian counterpart, vGPCR signals promiscu-
ously throughmultiple G protein subtypes to activatemultiple arms of
the MAPK/SAPK cascade, the Src family members and the PI3K/AKT
pathway. Transcription factor activation by vGPCR includes AP-1,
CREB, NFκB, and NFAT. Furthermore, in transgenic mice, vGPCR
expression recapitulates the most striking phenotypic features of KS
including multifocal spindle cell tumors including robust but aberrant
angiogenesis, and an inﬂammatory cell component (Guo et al., 2003;
Yang et al., 2000). Furthermore, vGPCR potentiates the tumor-forming
capacity of other KSHV gene products and a conditional knock-out
model shows that ongoing vGPCR expression is required to maintain
vGPCR-derived tumors (Jensen et al., 2005; Montaner et al., 2003).
These properties argue that vGPCR and its downstream signaling
events are crucial to the biology of KS and are promising anti-KSHV
targets. Targeting vGPCR for inhibition either directly or by
Fig. 1. vGPCR-induced Shp2 phosphorylation is Gαi-independent and Src-dependent,
but Erk1/2 independent. HEK 293 cells were transfected with pcDNA3.1+ as control
plasmid or with pcKSHV-vGPCR (A, C) or Gq(209L) plasmid (B) as shown. (A–C) After
48 h protein lysates were Western blotted for phospho-542-Shp2; membranes were
then stripped and re-probed for total Shp2. (A, B) Inhibitors were added 36 h post-
transfection where indicated. PTX (pertussis toxin, 100 ng/ml), PP2 (5 μM), PD
(PD98059, 25 μM). (C) Cells were co-transfected with Src-DN plasmid where noted. (D)
Cells were transfected with scrambled shRNA (sc) or shRNA targeted to Src (shSrc).
After 48 h, cells were transfected with vGPCR and protein harvested after 48 additional
hours. Western blot was performed for p542-Shp2, stripped and re-probed for total
Shp2. Total levels of Src are also shown to verify knockdown.
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signals potentially offers new therapeutic approaches for treating KS
and other KSHV-mediated diseases. There have been no signiﬁcant
successes discovering or designing potent inhibitors of constitutively
active GPCRs, so our work has focused on identifying key cellular
vGPCR effectors within the very complex network it activates.
In this study we focus on the cytoplasmic protein tyrosine
phosphatase (PTP) Shp2 and its role in vGPCR signaling. The PTPs
are crucial to the dynamic process of protein tyrosine phosphorylation
and dephosphorylation that regulates many basic cellular functions
including growth, survival, and migration. The non-receptor PTPs
include Shp1 and Shp2 which contain tandem amino-terminal SH2
domains, a catalytic domain and putative carboxy-terminal regulatory
sites (Koch et al., 1991; Qu, 2000). Shp2 is ubiquitously expressed,
while Shp1 is primarily found in hematopoietic cells and at low levels
in endothelial cells (Adachi et al., 1996; Yi, Cleveland, and Ihle, 1991).
Shp2 is a positive regulator of signaling pathways initiated by many
growth factors, including PDGF, EGF, IL-3, EPO, and GMCSF (Huyer and
Alexander, 1999; Neel and Tonks, 1997). Generally speaking Shp1 has
opposing effects to Shp2; Shp1 attenuates signals from EPO, IL-3, and
GM-CSF receptors and mediates inhibitory signals from γFc domains,
TCR, BCR, and the NK inhibitory receptor (Burshtyn et al., 1996; Chen
et al., 1996; D'Ambrosio et al., 1995; Yi et al., 1993). The importance of
the PTPs in cell homeostasis is evidenced by their deregulation by
human pathogens as diverse as protozoa, bacteria, and viruses
(Migone et al., 1998; Nandan and Reiner, 2005; Nandan et al., 2002;
Tsutsumi et al., 2006). Furthermore, overexpression of Shp2 and
reduction of Shp1 are associated with human leukemogenesis (Oka et
al., 2001; Xu et al., 2005). Very recent work shows a role for Shp2 in
endothelial cell proliferation and vessel growthmediated by the PI3K-
Akt and Erk1/2 pathways (Mannell et al., 2008). As discussed above,
vGPCR is highly angiogenic and signals by these same pathways. To
determine if Shp2 would be a feasible point at which to interfere with
vGPCR signaling and its downstream biologic effects, we studied the
phosphorylation status of Shp2 in the presence of vGPCR as well as the
effects of pharmacologic and genetic inhibition of Shp2 on vGPCR
signaling. In addition to work in HEK293 cells we also used lentiviral
transduction to study primary human endothelial cells. Our cell type
of choice is the blood outgrowth endothelial cell (BOEC). These cells
(“also called late-EPC”) are derived from human blood and display the
typical cobblestone morphology of endothelial cells, are uniformly
positive for vWF and incorporate acetylated LDL. They are all positive
for P1H12 (CD146), thromobomodulin, VEGFR2, VE-cadherin,
PECAM-1, CD34, and integrin αv. Of note they are uniformly CD14,
CD133 and CD45 negative. This phenotype is maintained through all
subsequent passages (up to 1012-fold expansion). Stimulation with
LPS or IL-1 results in increased ICAM-1 expression and the appearance
of VCAM-1 and tissue factor expression. (Jiang et al., 2007; Lin et al.,
2000). Furthermore, BOEC have recently been shown to be infected
with KSHV in vivo and are able to support the production of new
virions; they are therefore a very suitable cell type for KSHVmolecular
pathogenesis studies (Della Bella et al., 2008).
We have shown that the constitutive activity of vGPCR results in
phosphorylation of Shp2 at its regulatory C-terminal tyrosines and
that in turn, Shp2 is required for vGPCR activation of the MEK-ERK1/2
axis and the transcription factors AP-1 and NFκB as well as vGPCR-
induced endothelial cell migration. These results establish Shp2 as a
promising target to interfere with KSHV-induced changes in the
endothelial cell phenotype.
Results
KSHV vGPCR induces phosphorylation of Shp2 that requires Gαq and Src
Shp2 undergoes phosphorylation of tyrosine residues Y542 and
Y580 in its C-terminus that may regulate phosphatase activity orenhance scaffolding functions (Feng, Hui, and Pawson, 1993; Lorenz
et al., 1994; Minoo et al., 2004). We found in HEK293 that vGPCR
expression constitutively enhances phosphorylation of Shp2 Y542
(phospho-Y580 levels were high at baseline and not affected, data
not shown) (Fig. 1A). vGPCR is known to couple with both Gαi and
Gαq subunits depending on cellular context. To deﬁne the proximal
events by which Shp2 phosphorylation occurs, we used pertussis
toxin (PTX) to inhibit Gαi and found that Gαi subunits are not
required for either baseline or vGPCR-induced Shp2 phosphorylation.
This makes it highly likely that Gαq coupling explains vGPCR's effects
on Shp2. In the absence of a standard potent method to inhibit Gαq,
we used gain-of-function experiments with constitutively-active
mutant, Gq(Q209L)(Wu et al., 1992). Fig. 1B shows that Gq(Q209L)
causes phosphorylation of Shp2 at Y542. Together these data highly
suggest that it is a vGPCR-Gαq-Shp2 axis that we are observing in
HEK293. MEK is activated by vGPCR and is variably reported to signal
upstream or downstream of Shp2 depending on experimental
conditions. Pharmacologic inhibition of MEK (Fig. 1A) with
PD98059 shows that ERK1/2 activity is not required for Shp2
phosphorylation caused by vGPCR. Pharmacologic inhibition of Src
was also assessed for its effect since vGPCR can activate Src family
members (Cannon et al., 2003). Src inhibition by the potent and
speciﬁc inhibitor PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyr-
azolo[3,4-d]pyrimidine) resulted in dramatic decrease of both
baseline Shp2 Y542 phosphorylation and vGPCR-induced phosphor-
ylation. A dominant-negative (DN) construct of Src also inhibited
vGPCR-mediated phosphorylation, with no appreciable effect found
on baseline phosphorylation (Fig. 1C). The more modest effect of Src-
DN compared to PP2 is likely due to the inherent difﬁculties in
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role for Src we also used an shRNA construct from OpenBiosystems,
TRCN0000038153 (shSrc) to knock down Src. Knockdown was not
particularly efﬁcient, but even with a very modest level of Src
knockdown, levels of p542-Shp2 induced by vGPCR were blunted
(Fig. 1D). Together, these data show that in HEK 293 cells, vGPCR-
induced phosphorylation of Shp2 is Gαi-independent, likely Gαq-
dependent and is Src-dependent.
Shp2 is required for vGPCR-initiated signals that activate MEK, NFκB,
and AP-1
Having found that vGPCR potentially affects Shp2 function via
phosphorylation, we next assessed how inhibition of Shp2 would in
turn affect vGPCR-mediated events further downstream. NSC-87877
is a novel pharmacologic inhibitor of Shp2 phosphatase activity
(Chen et al., 2006). Fig. 2 shows that pharmacologic inhibition of
Shp2 inhibits vGPCR-mediated activation of MEK as measured by
phospho-ERK1/2 levels. NFκB and AP-1 activation by vGPCR are alsoFig. 2. Shp2 is required for vGPCR activation of MEK, NFκB and AP-1. (A) HEK 293 cells were
shown overnight. Western blot for phospho-ERK1/2was then done followed by blot for total
were transfected with pcDNA3.1+ or vGPCR along with the indicated luciferase reporter cons
5 h later. Luciferase activity was assessed 24 h post-transfection. Results were normalized to
(sc) or one of three different candidate shRNA plasmid constructs (Open Biosystems) to knoc
Shp2 shRNA (sh3), cells were transfected with vGPCR or empty plasmid. After 24 h protein w
for total Shp2, total vGPCR, and phospho-ERK1/2; the latter was stripped and re-probed for t
with vGPCR or control plasmid along with the indicated luciferase reporter plasmid and a β G
or Shp2 shRNA (sh3) were subjected to a sub-maximal dose (10 μM) of NSC-87877 overnigh
was normalized to corresponding total ERK1/2 band; each experimental point was then noat least partially Shp2-dependent (Fig. 2B). To support the above
pharmacologic data, we tested several shRNA plasmid constructs
against Shp2 from the pLKO library obtained from Open Biosystems.
Several candidate knockdown sequences were tested and in transient
assays we found that shRNA TRCN0000005003 (sh3) and shRNA
TRCN0000005004 (sh4) knocked down Shp2, whereas shRNA
TRCN0000005006 (sh6) and the scrambled shRNA (sc) did not (Fig.
2C). In agreement with the pharmacologic data, knockdown of Shp2
blunted vGPCR-induced activation of MEK, NFκB, and AP-1 without
affecting vGPCR expression levels (Figs. 2D, E). Residual transcription
factor activity could reﬂect either sub-total Shp2 inhibition or
perhaps contribution of Shp2-independent pathways in these cells.
Fig. 2F also shows that knock-down and pharmacologic inhibition of
Shp2 are additive and together reduce phospho-ERK1/2 levels to
baseline. Together, these experiments argue strongly that Shp2
contributes broadly to vGPCR signaling. It is very possible that
pathway cross-talk distal to Shp2 accounts for the broad effect; this is
under study but nonetheless, the data support Shp2 as an important
vGPCR effector.transfected with pcDNA3.1+ or pKSHV-vGPCR and incubated with NSC-87877 at doses
ERK1/2. Numbers above bands represent density normalized to control, lane 1. (B) Cells
truct and a constant amount of β–Gal plasmid. 25 μmNSC-87877 (grey bars) was added
β GAL levels. (C) HEK 293 were transfected with empty pcDNA3.1+, scrambled shRNA
k down Shp2 which was then assessed byWestern blot. (D) 48 h after transfection with
as harvested, transferred to PVDF which was then cut into three sections to immunoblot
otal ERK1/2. (E) Shp2 was knocked downwith shRNA as in (C), followed by transfection
AL construct for normalization. (F) Cells stably expressing either scrambled shRNA (sc)
t andWestern blot performed as above. (G) Density of phospho-ERK1/2 bands from 2F
rmalized to the control, lane 1. Bars=S.D. ⁎ denotes p≤0.05 by Student's t-test.
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both Gαi and Gαq
Although vGPCR can signal via both Gαq and Gαi subunits, these
interactions and their effects are cell-type speciﬁc; for example we
have found Gαi is required for vGPCR signaling in B cells but has
minimal contribution in HEK293 (reference 39 and unpublished
data). Although KSHV can infect many cell types in vitro, endothelial
and hematopoietic cells appear to be the main targets in vivo. We
therefore extended our studies into BOEC cells. BOEC are derived from
circulating endothelial cell progenitors, display a micro-vascular
phenotype, and as noted above have recently been found to harbor
KSHV infection in vivo (Della Bella et al., 2008; Lin et al., 2000, 2002).
To introduce exogenous DNA into these primary cells, we used
lentiviral transduction. Fig. 3A shows that with increasing multiplicity
of infection (MOI) of lenti-vGPCR, increasing amounts of vGPCR are
detectable by Western blot at 48 h and Fig. 3B conﬁrms the expected
spindled morphology induced by vGPCR. We found that vGPCR
expression caused very high levels of Shp2 phosphorylation at Y542
(Fig. 3C); we also found that unlike in HEK293, vGPCR caused
moderate increased phosphorylation of Y580 (data not shown). MEK
is activated by vGPCR in most cell types studied so far, so pERK levels
were also assayed as a positive control for vGPCR activity. Interest-
ingly, in distinction to HEK293, phosphorylation of Shp2 in BOEC was
partly inhibited by exposure to pertussis toxin overnight, supporting a
role for Gαi coupling (Fig. 3D, top). Furthermore, we found that under
serum-starved conditions, the effects of pertussis were consistently
more potent, causing reduction of phospho-Shp2 to near baseline
levels (bottom). The residual Shp2 phosphorylation in full medium
suggested that non-Gαi G protein coupling may be contributing as
well. Indeed, using a vGPCR mutant that signals only via Gαq (gift
John Nicholas), we saw Shp2 phosphorylation (Fig. 3E) (Liu et al.,
2004). Since lentiviral preps vary in concentration and even rigorous
quantiﬁcation is not always perfectly accurate, for this experiment, we
chose to use two MOI for each construct. This allowed us to select
points that expressed as near as possible the same amount of each
vGPCR construct.We then normalized phospho-Shp2 levels to loading
controls and vGPCR. Results of 3D and 3E argue for contribution of
both Gαq and Gαi to vGPCR-induced Shp2 phosphorylation. Impor-
tantly, we found that very short exposure to pertussis inhibits Shp2
phosphorylation; this effect is too fast to attribute to a change
cytokine levels so argues that via Gαi, vGPCR acts on Shp2Fig. 3. Lentiviral transduction of vGPCR into BOEC results in a Gαq- and Gαi-dependent
increase in phosphorylated form of Shp2. (A) BOEC cells were transduced with lenti-
vGPCR at MOI shown. After 48 h, RIPA lysates were immunoblotted for vGPCR. ‘NS'
designates a non-speciﬁc band. (B)Micrograph showing lenti-vGPCR induced change in
morphology from cobblestone to spindled. (C) BOEC were transduced with control
lentivirus (LKO) or lenti-vGPCR at MOI shown. At 48 h RIPA lysates were transferred to
PVDF which was cut and simultaneously immunoblotted for p542-Shp2, and pERK1/2;
blot was stripped and re-probed for total ERK1/2 as a loading control. Numbers above
bands represent p542-Shp2 band density normalized to corresponding loading control
and then normalized to control, lane 1. (D) BOEC were lenti-transduced with control
virus (LKO) or vGPCR at an MOI of 3. Forty-eight hours later, cells were serum-starved
(bottom panel) or not (top panel). At 60 h post-transduction PTX (100 nM), or the Src
inhibitor PP2 (5 μM) were added and protein lysates harvested and immunoblotted for
p542-Shp2 at 72 h post-transduction. Blots were stripped and re-probed for total Shp2.
Graph to right represents p542-Shp2 band densities normalized to loading control and
then normalized to peak levels in the corresponding lane 2. Bands were undetectable in
PP2 lanes and not represented graphically. (E) BOEC were lenti-transduced with LKO,
HA-vGPCR, vGPCR mutant #9 (inactive) or vGPCR mutant #15 (Gq-only), each at two
different MOI as shown. After 72 h cells were harvested for protein and immunoblotting
done for p542-Shp2, total Shp2 and vGPCR. Lanes 3, 4 and 7 had most similar amounts
of vGPCR construct and were used for densitometry in which p542-Shp2 and vGPCR
bands were normalized to tShp2 loading control and then p542-Shp2 normalized to
corresponding vGPCR band. Densities were normalized to inactive mutant, lane 3, and
fold change shown numerically above bands. (F) Lenti-vGPCR infected BOEC were
serum-starved overnight 60 h post-transduction. 30 min before harvesting protein,
100 nM PTX was added where indicated. p542-Shp2 bands were quantiﬁed and
normalized to tERK1/2 loading control and then to control, lane 1, and represented
graphically. PTX, pertussis toxin. Bars=S.D. ⁎p≤0.05.autologously (i.e. within the same cell) (Fig. 3F). Furthermore, since
Gαi inhibition in serum-starved conditions so potently reverses
vGPCR induced Shp2 phosphorylation, the contribution of Gαq is
likely via autocrine/paracrine effectors known to be upregulated by
vGPCR. Given these results we hypothesize that in full serum
conditions the role of the vGPCR-Gαq pathway far outweighs and
likely makes irrelevant the vGPCR-Gαi contribution to Shp2 activa-
tion. However, the ability of vGPCR to signal to Shp2 via Gαi may help
propagate vGPCR's pro-growth and survival effects in otherwise poor
growth conditions that may happen in KS tumors in vivo. Of note, as in
383T. Bakken et al. / Virology 397 (2010) 379–388HEK293, Src is absolutely required for both baseline and vGPCR-
induced Shp2 phosphorylation (Fig. 3D).
KSHV vGPCR-induced MEK activation in BOEC requires Shp2
Having established that vGPCR signaling induces Shp2 phosphory-
lation, we next investigated whether Shp2 was necessary to
downstream vGPCR signaling in BOEC. Fig. 4A shows that the Shp2-
speciﬁc pharmacologic inhibitor, PHPS1, blunts vGPCR-induced MEK
activity as represented by ERK1/2 phosphorylation. PHPS1 was used
here because it does not cross react with Shp1 as can NSC-87877. This
was not an issue in HEK293 which do not express Shp1; however, we
and others have found low levels of Shp1 expression in endothelial
cells. IP-10 was also used as a control in that it is an inverse-agonist
known to inhibit vGPCR by approximately 30% as measured by IP3
production (Geras-Raaka et al., 1998). To support the pharmacologicFig. 4. KSHV vGPCR-induced MEK activation in BOEC requires intact Shp2. BOEC cells
were lenti-transduced with control virus (LKO) or lenti-vGPCR (MOI 3). At 48 h RIPA
lysates were immunoblotted for phospho-ERK1/2, stripped and re-probed for total
ERK1/2. (A) At 36 h post-transduction, IP-10 (100 nM) or the Shp2 inhibitor PHPS1
(10 μM) was added. (B) 48 h prior to lenti-vGPCR transduction, BOEC were transduced
where shown with control lenti-LKO, lenti-Shp2-c/s, or -DSH2, dominant negatives of
Shp2. (C) Experiment performed as in (B) but using scrambled (sc) control versus lenti-
sh4. (D) BOEC were transduced with control lentivirus, lenti-Shp2-c/s, or lenti-DSH2 as
shown. After 48 h cells were serum-starved for 17 h in M199 (0.5% FBS), then exposed
for 20 min to conditioned medium from BOEC that had been previously transfected
with either control LKO lentivirus or lenti-vGPCR. Protein lysates were immunoblotted
for pERK1/2 and total ERK1/2. (E) Experiment performed as in (D) but using lenti-sc as
control versus lenti-sh4. Densitometry was performed and numbers over bands
indicate fold intensity changes as normalized to loading controls and then to control
bands.data, we also inhibited Shp2 by various genetic means. Fig. 4B shows
that Shp2 dominant-negatives Shp2-c/s and DSH2, the former
containing an inactivating substitution in the catalytic domain and
the latter a carboxy-truncated mutant lacking the catalytic domain
altogether inhibit ERK-1/2 phosphorylation caused by vGPCR. Fig. 4C
shows a similar effect from shRNA knockdown of Shp2. In some cases
slight increases in pERK1/2 are detectable with vGPCR but these
levels remain well below those induced in control cells and in some
cases pERK1/2 is undetectable. We found Shp2-c/s to be particularly
potent at suppressing both baseline and induced MEK activity. Due to
rather large doses of lentivirus required to inhibit or knock down
Shp2, relatively less lenti-vGPCR could be used and protein levels fall
below our ability to detect them by Western blot. However, Fig. 2D
reassures that lack of Shp2 does not affect vGPCR levels. Since vGPCR
is known to have potent paracrine effects via increased secretion of
various cytokines, we tested whether Shp2 was necessary in BOEC to
convey these vGPCR-mediated effects. Fig. 4D shows that Shp2
inhibition by both shRNA and dominant-negative constructs inhibits
MEK activation by vGPCR-conditioned medium in serum-starved
BOEC. This is somewhat expected since Shp2 is known to be involved
in signaling by many cytokines as discussed above. Levels of pERK1/2
induced by vGPCR-conditioned medium are not generally as high as
those in vGPCR expressing cells presumably because the latter are
subject to both paracrine/autocrine and direct vGPCR signaling. The
increase in ERK-1/2 phosphorylation by vGPCR-conditioned medium
is very modest so it is unclear if this would result in a biologically
signiﬁcant response, but it is feasible that even these small paracrine
effects of vGPCR may have an important role in modifying the KS
tumor microenvironment in vivo. It should also be pointed out that
although there is still some vGPCR-induced ERK-1/2 phosphorylation
when Shp2 is knocked down, the resulting levels are at or below
baseline thus supporting the notion that by inhibiting Shp2, vGPCR's
effects can also be inhibited. So together, these results show that Shp2
is a key step in vGPCR-initiated MEK activation, including that via
paracrine stimuli.
Shp2 is required for vGPCR-mediated AP-1 and NFκB activation
In addition to MEK activation, vGPCR activates transcription
factors (TF) such as AP-1 and NFκB. Both play roles in cell survival,
growth and migration. NFκB in particular is upregulated by various
KSHV gene products, and is a survival factor in both KSHV-infected B
cells and endothelial cells. We therefore wanted to establish if Shp2 is
required for activation of these TF by vGPCR speciﬁcally in endothelial
cells. Given technical difﬁculties with simultaneous co-transduction
multiple lentiviruses in our BOEC, we developed a tetracycline(tet)-
inducible lentivirus expressing vGPCR using vectors from Clontech.
This allowed us to split cells after lenti-transduction thereby
controlling for transduction efﬁciency rather than relying on an
additional reporter construct such as β-GAL. Fig. 5A shows that with
increasing MOI of tetracycline-inducible lenti-vGPCR, expression of
vGPCR is enhanced. Fig. 5B shows that both genetic and pharmaco-
logic inhibition of Shp2 inhibit vGPCR-induced NFκB and AP-1
activity.
Shp2 is required for vGPCR-induced BOEC migration
As discussed above, vGPCR expression in endothelial cells pheno-
mimics KSHV infection in vitro and in mouse models. Since effects
seen in signaling assays do not necessarily translate into phenotypic
effects, we wanted to know if Shp2 inhibition interferes with vGPCR-
induced endothelial cell migration. Using a standard scratch wound
assay, we found that both genetic and pharmacologic inhibition of
Shp2 inhibited vGPCR-induced migration of BOEC. Cells were grown
to conﬂuence and within each experiment we conﬁrmed that cell
density was within 10% across all points. A scratch was thenmade and
Fig. 5. Shp2 is required for vGPCR-mediated activation of NFκB and AP-1 in BOEC. (A)
BOEC were transfected with control virus or with pLVX-Tight-HA-vGPCR (HA-vGPCR)
and pLVX-Tet-On (Tet-On) at MOI shown. After 48 h cells were split equally and
doxycycline (2 μg/ml) was added where indicated for an additional 48 h. Protein
lysates were harvested and immunoblotted for HA-vGPCR total ERK1/2 as a loading
control. (B) BOEC were co-transduced with lenti-NFκB-luc reporter (top panel) along
with pLVX-Tight-HA-vGPCR and pLVX-Tet-On. After 24 h, cells were split, transduced
again with control LKO versus Shp2 dominant-negative lentiviruses, or lenti-scrambled
versus lenti-sh4. Doxycycline (doxy) was added to cause vGPCR expression where
indicated for 48 h, after which luciferase assay was performed. PHPS1 (10 μM) was
added 17 h before harvesting where shown. Bottom Panel: Identical to top except lenti-
AP1-luc reporter was used. Values were normalized to protein concentration. Bars=S.
D. ⁎ denotes p≤0.05 compared to maximal activation.
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of cell division (Fig. 6). At 10-h post-wounding, themicrophotographs
show the vGPCR-expressing cells oriented themselves perpendicu-
larly to the wound and far more had entered into the wound as
compared to control cells. Shp2 knockdown with lenti-sh4 had a
signiﬁcant inhibitory effect as did the PHPS1 which was more potent
and inhibited migration even below that of the control cells which did
display some baseline migration.
Discussion
KS tumors are highly angiogenic lesions of proliferating endothe-
lial cells accompanied by a prominent inﬂammatory cell component.
Although KSHV vGPCR is not the only viral product with the potential
to inﬂuence these processes, it is a potent and constitutively active
GPCR that conveys a survival advantage to endothelial cells in vitro
and causes KS-like lesions in transgenic mice. Therefore, understand-
ing how it signals will shed light not only on the role of vGPCR in KS
tumor formation, but will also inform as to which cellular pathwaysare deregulated by KSHVmore generally; perhaps by vGPCR at certain
points in viral reproduction, but via different viral proteins with
overlapping functions at other times. Indeed, given its lytic transcrip-
tion pattern, is likely that the role of vGPCR changes with the viral life
cycle and perhaps with KS lesion stage. Therefore, identifying key
points at which cellular signaling control is disrupted by vGPCR will
establish promising targets to interfere with KSHV replication and
pathogenesis. To that end, we sought to determine whether the
cytoplasmic phosphatase, Shp2, is an effector of vGPCR.
Given the increasing interest in the cytoplasmic PTPs as molecular
targets for cancer therapy and very recent data supporting a role of
Shp2 in normal angiogenesis, we investigated whether Shp2 is
required for at least some aspects of vGPCR signaling; either via
direct activation of Shp2 by vGPCR or indirectly by vGPCR-induced
secreted factors, or elements of both. It is estimated that 81 human
genes encode PTPs, which is very similar to the number for PTKs; and
as mentioned above, PTPs are dysregulated in a diverse set of
malignant and infectious human diseases (Alonso et al., 2004; Cheng
et al., 2007; Migone et al., 1998; Nandan and Reiner, 2005; Nandan et
al., 2002; Tsutsumi et al., 2006). For all these reasons, PTPs are
increasingly the target of medicinal chemistry research (Hellmuth et
al., 2008; Noren-Muller et al., 2006; Qu, 2000).
Our work in HEK293 and in BOEC shows that vGPCR causes
phosphorylation of Shp2 at putative regulatory sites. Importantly, the
proximal events in this pathway differed between cell types in that a
vGPCR-Gαi axis was easily demonstrated in BOEC but not in HEK293.
Presumably this is due to differences in expression levels of proximal
effectors. Nonetheless, a vGPCR-Gαq axis was also at work in BOEC,
although since PTX potently inhibits the vGPCR effect in serum-
starved conditions, it may be that the role of Gαq is indirect in that it is
required for vGPCR-mediated transcriptional upregulation of secreted
cytokines which in turn signal via Shp2. We have also shown that
Shp2 is required for successful conduction of various vGPCR-mediated
signaling events. Although inhibition of Shp2 did not always
completely abrogate vGPCR function, it is important to note that
without Shp2, vGPCR's signaling effects were very near to baseline
levels. Consistent with recent ﬁndings that Shp2 is involved in
angiogenesis, we found that vGPCR-induced endothelial cell migra-
tion is Shp2-dependent.
Although this study argues for Shp2 as a potentially important
convergence point for vGPCR signaling and as a promising target to
disrupt KSHV-induced pathology, several questions remain and are
under study. For instance, there is some debate over whether Shp2
can function as a scaffolding molecule (via its SH2 domains)
regardless of an intact catalytic domain, or whether all Shp2 functions
require its intact phosphatase activity. There is also some controversy
regarding the relationship of potential regulatory tyrosine and serine
sites in Shp2 and its catalytic activity; with some data showing that
these phosphorylations are required and other not. We are currently
investigating how vGPCR affects Shp2 phosphatase activity. We are
also further exploring the mechanism of vGPCR signaling to Shp2
which is only partially elucidated here in that we looked only at
canonical heterotrimeric G protein coupling. Non-canonical vGPCR
signaling is an emerging ﬁeld and there is a very small literature
describing GPCRs that contain putative immunoreceptor tyrosine
inhibitory motifs (ITIM). ITIM motifs bind to and activate Shp1 and
Shp2 among other phosphatases, by inducing a conformational
change (Poole and Jones, 2005). We have identiﬁed a putative ITIM
motif on the intracellular tail of vGPCR; our preliminary mutational
studies and protein-protein binding assays support this as a bone ﬁde
ITIM motif.
The overall role of vGPCR to the biology of KS and the KSHV life
cycle is not entirely clear. Although many investigators had early
argued for a primarily paracrine role for vGPCR in tumor develop-
ment, Lira's group has recently developed a mouse model in which
vGPCR and LacZ are expressed simultaneously and conditionally,
Fig. 6. Shp2 is required for vGPCR-induced migration in BOEC. (A) BOEC were lenti- transduced with control virus LKO or vGPCR with and without lenti-sh4 to knockdown Shp2.
After 48 h cells reached conﬂuence and a scratch “wound”was made with a pipette tip and medium changed to low-serum (0.1% FBS) without additional supplements. The width of
the scratch and the number of cells migrating back into the wound were quantiﬁed using NIH ImageJ, 10 h post-wounding (width measured in arbitrary units). (B) Shp2 was
inhibited by PHPS1 (10 μM) where indicated for 12 h prior to wounding. Error bars represent S.D. One representative of 3 experiments is shown.
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(Grisotto et al., 2006). Using this model they argue that vGPCR also
has a direct proliferative effect on endothelial precursor cells. Of
course paracrine effects are likely also at work; indeed, vGPCR-
expressing hematopoietic cells in vitro express cytokines known to be
growth factors for endothelial cells, most prominent of which is VEGF
(Cannon, Philpott, and Cesarman, 2003). It is possible then that cells
undergoing lytic KSHV infection not only produce new virions but via
vGPCR help to condition the microenvironment such that it is
conducive to ongoing KSHV infection and replication. A direct role
for vGPCR in angiogenesis or survival is somewhat harder to explain in
that vGPCR is a lytic KSHV gene product expressed in cells destined to
produce new virions and die. There is however, some evidence that
the vGPCR may be regulated outside of the canonical latent-to-lytic
switch by cellular factors (Liang and Ganem, 2004). Another direct
role could occur early in de novo KSHV infection when in vitromodelsshow that there is a lytic burst of viral gene transcription prior to the
establishment of latency. It is possible in this setting that vGPCR
conveys survival and growth effects to offset a cellular response to
viral infection. As a very proximal effector of vGPCR, Shp2 could play a
role in any or all of these potential vGPCR functions. Of course
studying the broader role of PTPs in the context of KSHV infection is
also important in that there may be additional viral mechanisms to
perturb these pathways that ultimately contribute to KSHV-induced
pathology.
Materials and methods
Plasmids and chemicals
PD98059, NSC-87877, and pertussis toxin (PTX) were from
Calbiochem. PHPS1 is from Asinex (Moscow, Russia). IP-10 is from
386 T. Bakken et al. / Virology 397 (2010) 379–388Peprotech (Rocky Hill, NJ). PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine) was from Calbiochem. pcKSHV-
vGPCR has been previously described (Arvanitakis et al., 1997). The
pSG5-vGPCR.15 mutant was kind gift of John Nicholas and the HA-
vGPCR expression construct was a gift of Pinghui Feng. pCMV-Shp2
WT and pCMV-Shp2-c/s were from Benjamin Neel via Addgene
(Cambridge, MA). The C-terminal deletion Shp2 mutant (DSH2) was
created by PCR using pCMV-Shp2 WT as template and the following
primers: 5′-ATGGATCCACCATGACA TCGCGGAGATGGTT-3′ and 5′-ATGCGGCCGCAC-
GAGTCGTGTTAAG-3′. Plasmids to generate lentivirus encoding shRNA
sequences to Shp2 were obtained from Open Biosystems; sh3 (clone
Id TRCN0000005003), sh4 (clone Id TRCN0000005004), sh6 (clone Id
TRCN0000005006). Constructs from the Open Biosystems library are
designed by algorithm to target a given transcript but need to be
tested and validated by the end user. As demonstrated in the Results,
we found sh3 and sh4 to be effective, but sh6 ineffective. For Src
knockdown we used clone ID TRCN0000038153. Luciferase reporter
constructs include pAP1(PMA)-TA-Luc, pNFκB-TA-Luc (Clontech).
Cell culture and conditioned medium
HEK293 cells were maintained in DMEM plus 40 mg/l gentamicin
with 10% FBS (Invitrogen) at 37 °C, 5% CO2. BOEC cells were obtained
from Dr. Robert Hebbel, University of Minnesota and maintained in
EGM-2 plus Bullet Kit (Lonza, Walkersville, MD) on collagen-coated
plates and dishes (Lin et al., 2000). To produce conditioned medium,
BOEC were transduced with control lentivirus or lenti-vGPCR; at 48 h
cells were washed and M199 (Invitrogen) plus 0.5% FBS was added.
48 h latermediumwasﬁltered through a 45 μmsyringe ﬁlter and either
used immediately or aliquoted and frozen at−80 °C for future use.
Transfections
Transfections of HEK293 or HEK293T were performed on expo-
nentially growing cells using a 3:1 ratio of Fugene6 (Roche) to
plasmid DNA as per manufacturer's recommendations.
Luciferase assays
Cells were transfected or transduced with luciferase reporter
plasmids or lentiviruses respectively, as well as other constructs
appropriate to each experiment. After 24–48 h, lysates were prepared
using the provided lysis reagent as per the manufacturer's directions
(Promega, Madison, WI). Assays were performed using 10 μl of lysate
and 50 μl of beetle luciferin in a Luminoskan Ascent FL (Thermo Fisher
Scientiﬁc, Waltham, MA) using a 10-s read time. For HEK293, cells
were co-transfected with a β-galactosidase plasmid and luciferase
results normalized to β-gal levels as per manufacturer's protocol
(Promega, Madison, WI). In the case of BOEC transductions, cells were
divided after transfection, so efﬁciency was inherently controlled for
and luciferase levels were normalized to protein levels; protein was
quantiﬁed using DC Protein Assay Kit II (Bio-Rad, Hercules, CA).
Western blotting and antibodies
Both HEK293 and BOEC cells were lysed with standard RIPA buffer
with phosphatase and protease inhibitor cocktails (Sigma). Protein
was quantitated by the Bradford method and loaded onto 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels.
Semidry transfer to PVDF (Millipore, Billerica, MA) was performed
using transfer buffer, 48 mM Tris, 39 mM glycine, 0.037% SDS, and 20%
methanol. Blots were probed with 1:1000 dilution of primary
antibody (Ab) overnight at 4 °C in the case of phospho-speciﬁc
antibodies, or at room temperature for 1 h for all others. HRP-
conjugated secondary Ab was added after washing and detected by an
enhanced chemiluminescence system (ECL) (Amersham, Little Chal-font, UK). Antibodies used: anti-Shp2(C-18) (Santa Cruz, Santa Cruz,
CA); antibodies to phosphorylated forms of AKT (9271), ERK1/2
(9101), Try542-Shp2 (3751) and Tyr580-Shp2 (3754) were all from
Cell signaling Technologies (Danvers, MA) as was anti-AKT ( 9272).
Anti-ERK1/2 (06182) was from Millipore/Upstate (Billerica, MA).
Anti-HA antibody (16B12)was from Covance (Princeton, NJ) and anti-
n-terminal vGPCR was a kind gift of Gary Hayward of Johns Hopkins
University. Western blot autoradiographs were scanned with an
Epson V700 Photo scanner. Images were cropped and brightness/
contrast adjusted with Adobe Photoshop 6.0. Notation for ﬁgures was
donewith Deneba Canvas 8.0. Band density was quantitated from ﬁlm
using a Kodak Image Station 2000R and software Kodak MI v4.0.4.
Lentivirus production and infection
Transgenes were PCR-cloned to contain an upstream BamHI site
and a downstream NotI site and ligated into BamHI/NotI digested
pHR-CSGW (gift of Adrian Thrasher). For luciferase reporter lenti-
viruses, pHR-CSGW was digested with EcoRI, blunt ended, and then
digested with NotI to remove both the SFFV promoter and the GFP
transgene. Into this site was ligated the sequence from the
transcription blocker through the end of the luciferase coding region
from the AP1 and NFκB reporter plasmids (see above), using primers,
5′-CGGATATCCGGCCGCAATAAAATATCTT-3′ and 5′-ATAAGAATGC-
GGCCGCCCGACTCTAGAATTACAC-3′. To obtain pseudotyped lentivirus
(recombinant HIV-1 with vesicular stomatitis virus G (VSV-G)
envelope protein), we used the gene delivery and production system
developed by Naldini et al. (1996). In short, HEK293T cells were
transfected with pHR-CSGW-transgene, p8.74 and pMD.G in a 1.5:1:1
ratio. At 72 h, supernatants were ﬁltered through a 0.45 μm syringe
ﬁlter then ultracentrifuged for 2 h at 22,000 rpm. Pellets were
resuspended in Opti-Mem, aliquoted and frozen. Titering was done by
Western blot of 3 μl and 15 μl of lentivirus for p24 using antibody from
Abcam (ab9071) (Cambridge, MA). A sample of lentivirus that
expresses GFP and had been previously titered by ﬂow cytometry
was loaded as a control. BOEC were transduced at approximately 50%
conﬂuence by resuspending lentivirus in 20 μl of Opti-Mem which
was then added to cells and left on for 48–72 h, depending on
experimental set-up. For tetracycline-inducible lentivirus experi-
ments, HA-vGPCR was cloned into pLVX-Tight-Puro and cells were
infected with equal MOI of this virus and pLVX-Tet-On (Clontech)
along with the transcription factor reporter lentivirus. After 48 h, cells
were split and subjected to further transduction with control,
dominant-negative or knock-down lentis; doxycycline was added
where stated in ﬁgure legends. In the case of shRNA knock-down,
plasmid to generate lentivirus encoding various candidate knock-
down sequences were obtained from Open Biosystems (see Materials
and methods).
Scratch assay
BOEC cells were seeded into 6 well plates and allowed to reach
conﬂuency. A 200-μl pipette tip was used to wound cells in a straight
line across the well. Full medium was than replaced with M199 with
0.5% FBS to minimize the effects of cell division. Cells were
periodically examined and micrographs obtained with an Axiovert
200M, A-plan 10×/0.25 objective, and Axiocam (Zeiss). The width of
the wound and number of cells that had migrated into wound were
quantitated using NIH ImageJ (http://rsb.info.nih.gov/ij/). BOEC
were previously transduced or chemically treated as appropriate for
each experiment.
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